1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13:8–10. PMID:
7799047.

2. Uppal A, Ferguson MK, Posner MC, Hellman S, Khodarev NN, Weichselbaum RR. Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis. 2014; 31:735–748. PMID:
24968866.

3. Park JW, Jang WS, Koh DH, Ham WS, Rha KH, Hong SJ, et al. Impact of early salvage androgen deprivation therapy in localized prostate cancer after radical prostatectomy: a propensity score matched analysis. Yonsei Med J. 2018; 59:580–587. PMID:
29869455.

4. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005; 294:238–244. PMID:
16014598.

5. Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in oncology. J Natl Compr Canc Netw. 2019; 17:479–505. PMID:
31085757.
6. Koo KC, Dasgupta P. Treatment of oligometastatic hormone-sensitive prostate cancer: a comprehensive review. Yonsei Med J. 2018; 59:567–579. PMID:
29869454.

7. Selvik HA, Thomassen L, Logallo N, Næss H. Prior cancer in patients with ischemic stroke: the Bergen NORSTROKE study. J Stroke Cerebrovasc Dis. 2014; 23:919–925. PMID:
24075585.

8. Grisold W, Oberndorfer S, Struhal W. Stroke and cancer: a review. Acta Neurol Scand. 2009; 119:1–16. PMID:
18616624.

9. Levine SR. Hypercoagulable states and stroke: a selective review. CNS Spectr. 2005; 10:567–578. PMID:
16155513.

10. Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015; 194:1537–1547. PMID:
26196735.

11. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet. 2002; 360:103–106. PMID:
12126818.
12. Strong VE, D'Angelica M, Tang L, Prete F, Gönen M, Coit D, et al. Laparoscopic adrenalectomy for isolated adrenal metastasis. Ann Surg Oncol. 2007; 14:3392–3400. PMID:
17665267.

13. Aoun F, Peltier A, van Velthoven R. A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer. Biomed Res Int. 2014; 2014:501213. PMID:
25485280.

14. Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes and treatment considerations. Nat Rev Urol. 2017; 14:15–25. PMID:
27725639.

15. Keating NL, O'Malley A, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2012; 104:1518–1523. PMID:
23210129.

16. Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al. Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study. Prostate Cancer Prostatic Dis. 2014; 17:338–342. PMID:
25134939.

17. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007; 110:1493–1500. PMID:
17657815.

18. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007; 99:1516–1524. PMID:
17925537.

19. Jespersen CG, Nørgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014; 65:704–709. PMID:
23433805.

20. Li GQ, Fan J, Liu J, Wang W, Wang M, Qi Y, et al. Impact of cerebrovascular disease mortality on life expectancy in China. Biomed Environ Sci. 2014; 27:169–175. PMID:
24709097.
21. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009; 302:866–873. PMID:
19706860.

22. Babiker AA, Ekdahl KN, Nilsson B, Ronquist G. Prothrombotic effects of prostasomes isolated from prostatic cancer cell lines and seminal plasma. Semin Thromb Hemost. 2007; 33:80–86. PMID:
17253194.

23. Kaur H, Siemens DR, Black A, Robb S, Barr S, Graham CH, et al. Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: a prospective, longitudinal study. Can Urol Assoc J. 2017; 11:33–38. PMID:
28443142.
